Hot off the Press!

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

​​​​​​Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray called AnQlar™. The drug is intended to prevent the spread of viruses such as influenza, COVID-19 and similar flu-like viruses. The studies were performed at Altasciences’ preclinical facilities located in Columbia, MO, and Scranton, PA, and are currently ongoing.
 

Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)

​​​​​​A Phase I trial of Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, was successfully completed at Altasciences’ clinical facility in Montréal. The study was performed in a group of 80 healthy participants, to evaluate safety, tolerability, and pharmacokinetics of the drug. If successful, CMX-2043 could be a vital step to treating TBI, which is responsible for 60,000 deaths per year in the U.S.
 

Let's Promote Your Project!

You may also be interested in:

• The Altascientist Issue No. 34: Toxicokinetics, Pharmacokinetics, and Pharmacodynamics
• Blog: Nonclinical Safety Pharmacology Programs—What You Need to Know
• Blog: Drug Development Timelines: How Health Canada’s 30-Day Regulatory Review Process Could Provide an Advantage
• Fact Sheet: Infectious Diseases
• Press Releases: View More